Relapsed or Refractory Acute Myeloid Leukemia (AML) (DBCOND0068723)

Identifiers

Synonyms
Acute Myeloid Leukemia (Relapsed/Refractory) / Relapsed/Refractory Acute Myeloid Leukemia (AML) / Relapsed/Refractory Acute Myeloid Leukemia / Relapsed/Refractory Acute Myeloid Leukemia(AML) / Relapsed /Refractory Acute Myeloid Leukemia / Relapsed or Refractory Acute Myeloid Leukemia / Relapse or Refractory Acute Myeloid Leukemia

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT01806116
Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantationtreatment4unknown_status
NCT03473457
CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatmentNot Availableterminated
NCT06549790
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment1recruiting
NCT02665143
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemiatreatment2completed
NCT05332054
Long-Term Follow-up StudyNo drug interventionsNot AvailableNot Availableenrolling_by_invitation
NCT06541405
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment0recruiting
NCT03190278
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment1recruiting
NCT05548088
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment1unknown_status
NCT03318016
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemiatreatment1terminated
NCT03886831
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesNo drug interventionstreatment1completed
NCT06541444
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment0recruiting
NCT03904069
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AMLtreatment1withdrawn
NCT05061147
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)treatment1 / 2unknown_status
NCT05722171
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment0recruiting
NCT05731219
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment1recruiting
NCT06084819
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemiatreatment2recruiting
NCT05518357
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment1completed
NCT05627466
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNot AvailableNot Availableno_longer_available
NCT03504410
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLtreatment3terminated
NCT03541369
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaNo drug interventionstreatment1terminated
NCT06049667
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological MalignanciesNo drug interventionstreatment1recruiting
NCT02626338
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AMLtreatment1 / 2completed
NCT05143996
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)No drug interventionstreatment1recruiting
NCT05662904
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AMLtreatment1not_yet_recruiting
NCT05951855
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patientstreatment2recruiting
NCT02249091
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)treatment2completed
NCT02215629
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemiatreatment1withdrawn
NCT05522192
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemiatreatment1 / 2recruiting
NCT05726110
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemiatreatment3recruiting
NCT04478695
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemiatreatment1terminated
NCT03755154
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemiatreatment1completed
NCT04176393
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutationtreatment1completed
NCT02675452
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemiatreatment1completed
NCT05038800
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)treatment1terminated
NCT04842370
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AMLtreatment1unknown_status
NCT04666649
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)treatment1active_not_recruiting
NCT03765541
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemiatreatment3recruiting
NCT05787496
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsNo drug interventionstreatment1recruiting
NCT02623582
CD123 Redirected Autologous T Cells for AMLtreatment0terminated
NCT05241093
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)treatment2recruiting
NCT02074839
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutationtreatment1recruiting
NCT05345938
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemiatreatment1 / 2terminated
NCT03218683
Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.treatment1terminated
NCT05241106
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)No drug interventionstreatment2recruiting
NCT04113616
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)treatment1 / 2terminated